Primary Sclerosing Cholangitis clinical trials at UCSF
3 in progress, 1 open to eligible people
Primary sclerosing cholangitis is a condition that results in liver bile duct scarring. UCSF is conducting research on adults who have this disease to identify the risks involved. The study is aimed at developing models to predict disease progression.
Liver Cirrhosis Network Cohort Study
open to eligible people ages 18 years and up
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.
San Francisco, California and other locations
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Sorry, not currently recruiting here
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
San Francisco, California and other locations
PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Sorry, in progress, not accepting new patients
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
San Francisco, California and other locations
Last updated: